Abstract
Hereditary transthyretin amyloidosis (hATTR), a progressive, debilitating, and ultimately fatal disease, causes multisystem dysfunction. We report long-term efficacy and safety for inotersen, an antisense oligonucleotide inhibitor of transthyretin protein production.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
